deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT02975271

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury (AUBURN)

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury

Sponsor: Vyne Therapeutics Inc.

Conditions Burns Pruritus
Interventions Placebo Serlopitant
Updated 13 times since 2017 Last updated: May 18, 2021 Started: Nov 30, 2016 Primary completion: Jan 17, 2017 Completion: Jan 17, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business Reasons

Other terminated trials from Vyne Therapeutics Inc.

More terminations from Vyne Therapeutics Inc.

Other Burns trials with similar outcome

Browse all Burns trials

This PHASE2 trial investigates Burns and Pruritus and is currently terminated or withdrawn. Vyne Therapeutics Inc. leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Mar 2018 · 9 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2020 · 26 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Apr 2022 · 10 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2021 — Apr 2022 [monthly]

    Terminated PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — Jun 2021 [monthly]

    Terminated PHASE2

  2. Sep 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Aug 2020 — Sep 2020 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Aug 2020 [monthly]

    Terminated PHASE2

  5. Mar 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  6. Jun 2017 — Mar 2018 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  7. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vyne Therapeutics Inc.
Data source: Vyne Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations